A New Framework for Assessing Digital Health Technologies

By Staff Writer

October 23, 2023

The Importance of Developing a Brand-New Structure

The field of digital health technologies (DHTs), which offers novel solutions for the delivery of healthcare, is undergoing rapid development. However, doing an evaluation of their usefulness presents a novel obstacle due to the fact that conventional frameworks for health technology such as pharmaceuticals and medical equipment cannot be directly applied to them. The Peterson Health Technology Institute (PHTI) has established a value assessment framework to guide evaluations of digital health technologies (DHTs), with the goals of creating evidentiary standards for technology developers and assisting organisations in adopting impactful DHTs. This methodology is illustrated below.

The Framework of the Peterson Health Technology Institute

The evaluation of the value of DHTs must pay close attention to the ways in which they affect the economy. DHTs are projected to improve care outcomes while simultaneously reducing overall costs, or give dramatically improved access at significantly cheaper costs than other options. This is in contrast to new medications, which often increase the cost to the health system. Because of the one-of-a-kind characteristics of DHTs, the PHTI paradigm places a greater emphasis on cost-effectiveness analysis over long-term cost-benefit analysis.

The methodology also takes into account the larger economic benefits of DHTs, such as increases in productivity as well as decreases in the amount of time as well as money spent by families and caregivers. However, these advantages will not be considered in the major study of how the budget would be impacted.

Digital Health Technologies

The PHTI’s approach for evaluating DHTs is a significant step towards standardising the evaluation of these technologies and marks an important step in that direction. The framework will guide technology developers in their product development by defining clear and thorough criteria of evidence, and it will assist healthcare organisations in making educated decisions about using DHTs.

The PHTI’s framework will, in the end, contribute to improved health outcomes as well as cost savings in the healthcare sector. This will be accomplished by guaranteeing that only the DHTs that are the most effective and cost-efficient will be adopted.

Reference url

Recent Posts

Mavyret acute hepatitis C
         

Mavyret Acute Hepatitis C: Pioneering Treatment Expansion and Economic Implications

🌟 Did you know that the FDA has just approved the first-ever treatment specifically for acute Hepatitis C?

AbbVie’s Mavyret (glecaprevir/pibrentasvir) is now set to improve the way we think about HCV interventions, enabling earlier treatment to reduce long-term complications and improve patient outcomes. This approval not only addresses an urgent public health need but also aligns with evolving healthcare delivery models focused on cost-effective solutions.

Curious to learn more about the implications of this significant advancement in hepatitis care? Review the full article for insightful analysis on the future of HCV treatment!

#SyenzaNews #HealthcareInnovation #MarketAccess #HealthEconomics

HIV vaccine trials
    

Advancements in HIV Vaccine Trials: Promising Results from mRNA Strategies

🌍 Are we finally making strides in the fight against HIV?

Recent phase 1 vaccine trials using mRNA technology have shown promising results in activating immune responses that could lead to broadly neutralizing antibodies (bnAbs). This innovative approach not only addresses HIV’s rapid mutation but also offers critical insights for high-prevalence regions.

Dive into the full article to explore how these trials could shape the future of HIV prevention and what it means for global health!

#SyenzaNews #globalhealth #HIV #clinicaltrials

EHK clusters 2026 report
       

EHK Clusters 2026 Report: Enhancements in Dutch Risk Equalization for High-Cost Pharmaceuticals

🚀 Are you curious about how the Dutch healthcare system is adapting to high-cost pharmaceuticals?

The latest EHK clusters report for 2026 brings crucial updates to the risk-equalization model, enhancing equity among health insurers while closely managing skyrocketing costs. With innovative clustering techniques and revised reimbursement figures, these changes aim to improve access and accountability in an increasingly competitive healthcare landscape.

Dive into the full article to uncover the implications for health economics and policy!

#SyenzaNews #HealthEconomics #HealthcareInnovation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.